Shock, Septic Clinical Trial
Official title:
The Effect of Hydrocortison Treatment on Angiotensin II and Angiotensin Receptors in Patients Suffering From Septic Shock: A Prospective Observational Study
This study aims to evaluate the role of angiotensin II, AT1, and AT2 on catecholomine responsive and catecholomine resistant septic shock, and the effect of hydrocortisone traetment on catecholomine resistant septic shock and angiotensin II, AT1, and AT2.Angiotensin II can be used as a biomarker of vasoplegia observed in refractory septic shock unresponsive to catecholamine. In these patients; therapeutic effect of hydrocortisone on hypotension was performed by decreasing AT 2 level, AT2 should be investigated as a therapeutic target in the treatment of vasoplegia-induced hypotension and SVRI measured by minimally invasive cardiac output method suggests that it can be used as a useful parameter in the diagnosis and follow-up of vasoplegia.
This study will be enrolled 40 patients diagnosed with septic shock according to Sepsis 3 criteria. The patients with septic shock who needed a noradrenaline infusion rate of up to 0.5µg/kg/min to maintain MAP>65 mmHg will be classified as control group (n=20) and the ones who required a noradrenaline infusion rate above 0.5µg/kg will be classified as hydrocortisone group (n=20). Blood samples will be taken for analysis of plasma angiotensin II, AT1, AT2 levels at the time of diagnosis, one hour after and on the 3rd day of the bundle and the hydrocortisone treatment. Hemodynamic parameters simultaneously obtain by continuous minimal invasive cardiac output measurement method will record. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03592693 -
Vitamin C, Hydrocortisone and Thiamine for Septic Shock
|
Phase 2 | |
| Terminated |
NCT01639664 -
COMPACT 2 - COMbining Plasma-filtration and Adsorption Clinical Trial 2
|
N/A | |
| Withdrawn |
NCT01601938 -
Selenium Replacement and Serum Selenium Level in Severe Sepsis and Septic Shock Patients
|
Phase 2 | |
| Recruiting |
NCT00335907 -
Protocol-driven Hemodynamic Support for Patients With Septic Shock
|
N/A | |
| Completed |
NCT00000574 -
Ibuprofen in Sepsis Study
|
Phase 3 | |
| Recruiting |
NCT04910841 -
Feasibility of Using the "CGM GUARDIAN 2" Interstitial Fluid Glucose Measurement System in Intensive Care Medicine
|
N/A | |
| Active, not recruiting |
NCT04079829 -
Postoperative Respiratory Abnormalities
|
||
| Recruiting |
NCT04569942 -
Australasian Resuscitation In Sepsis Evaluation: FLUid or Vasopressors In Emergency Department Sepsis
|
Phase 3 | |
| Recruiting |
NCT04934943 -
"Mini Fluid Challenge Assessment: a Comparison Among Three Hemodynamic Tools"
|
||
| Completed |
NCT01310790 -
Strategy of Early Improvement of Tissue Oxygenation Decrease the Mortality of Severe Sepsis and Septic Shock
|
Phase 4 | |
| Completed |
NCT00241228 -
Haemofiltration Study : IVOIRE (hIgh VOlume in Intensive Care)
|
N/A | |
| Completed |
NCT00046072 -
A Safety and Efficacy Study of Intravenous E5564 in Patients With Severe Sepsis
|
Phase 2 | |
| Withdrawn |
NCT03122678 -
Thiamine Supplementation in Patients With Septic Shock
|
Phase 1 | |
| Recruiting |
NCT06155812 -
Multimodal Vasopressor Strategy in Septic Shock
|
Phase 2/Phase 3 | |
| Completed |
NCT04178148 -
Personalized Dose Optimization of Amikacin Guided by Pharmacokinetic Modeling Software in Patients With Septic Shock
|
N/A | |
| Completed |
NCT01453270 -
Emergency Department Management of Sepsis Patients: A Goal-Oriented Non-Invasive Sepsis Trial
|
N/A | |
| Completed |
NCT04576819 -
Role and Mechanisms of Lipid and Lipoprotein Dysregulation in Sepsis
|
||
| Active, not recruiting |
NCT04055909 -
Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock
|
Phase 2 | |
| Suspended |
NCT03193164 -
Neuromuscular Electrical Stimulation and Septic Shock
|
N/A | |
| Withdrawn |
NCT02454348 -
NOrepinephrine and VasoprEssin Versus Norepinephrine aLone in Critically Ill Patients With Septic Shock
|
Phase 4 |